Sign inJoin waitlistJoin the waitlist

David McCall

Physician · University of Texas M D Anderson Cancer Center

Credentials: · · ·

History

University of Texas M D Anderson Cancer Center
2025–Present

Pediatric Hematology Oncology
University of Texas Health Science Center at Houston
2017–2020
Pediatrics
The University of Alabama
2014–2017
Med Coll of Georgia
2010–2014

Research

Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
Review · Nature Reviews Clinical Oncology · 2019 · 185 citations
The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma
Journal for ImmunoTherapy of Cancer · 2014 · 124 citations
Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Cancers · 2021 · 57 citations

Branko Cuglievan
50 papers · 1 as a fellow
Cesar Nunez
36 papers
Amber Gibson
33 papers · 5 as a fellow
Michael Roth
29 papers
Miriam Garcia
29 papers
Priti Tewari
17 papers · 4 as a fellow
Nicholas Short
12 papers
Irtiza Sheikh
11 papers · 1 as a fellow
Jeremy Connors
11 papers · 3 as a fellow
Courtney DiNardo
10 papers
Ghayas Issa
10 papers
Demetrios Petropoulos
9 papers

Clinical trials

A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2025–2031
A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias
Principal investigator · Recruiting · Phase 1
M.D. Anderson Cancer Center
2025–2031
A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias
Principal investigator · Recruiting · Phase 1
M.D. Anderson Cancer Center
2024–2030
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2023–2029